nonvalvular AF comparable to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mortality. 7 Current standard procedure of LAA closure device implantation is guided by intraprocedure transesophageal echocardiography (TEE) and under general anesthesia. In some district hospital of Indonesia, TEE probe is not available and numbers of anesthesiologist are limited. Therefore, we prospectively study the feasibility of LAA closure device implantation guided by fluoroscopy only and without general anesthesia.
| ME THODS

| Patients
A consecutive of 53 patients (aged 67.5 ± 8.70 years, 37% are women) with nonvalvular AF participated in this study. Written informed consents are obtained from all participants. In 25 patients, ACPs implantation guided by fluoroscopy only and without general anesthesia (Group A). In another group of 28 patients, ACPs implantation was using standard protocol (Group B). To be eligible for this study, patients must have a CHA 2 DS 2 VASc score 8 of at least 2 and HASBLED score 9 of at least 3, and unsuitable for long-term anticoagulant therapy. Exclusion criteria are the presence of thrombus in the left atrium, acute decompensated heart failure, contraindications for transseptal puncture and require long-term anticoagulant therapy due to any other indication.
Extracardiac source of stroke was excluded in both groups.
| LAA sizing
Preprocedural TEE 10 and/or cardiac computed tomography (CCT) 11 are used to exclude the presence of thrombus in left and right atrium as well as to determine LAA diameters and morphology.
A 
| Procedure of ACP implantation
In Group A, ACP implantation procedure is performed on conscious condition with local anesthesia of bilateral inguinal area. In Group B, ACP implantation is performed using standard protocol. 12 Procedure is performed under general anesthesia. In brief, the procedure comprised of (a) TEE-guided transseptal puncture which targets more inferior part of the fossa ovalis, (b) LAA angiography in order to measure landing zone and ostial diameter which is then confirmed by TEE, (c)
Step-by-step ACP placement, and (d) Finally appropriate position of ACP and absence of residual flow jet is confirmed by TEE before the device is unscrewed from the delivery system. 
| Follow-up
The mean follow-up period was 75 weeks. 
| RE SULTS
The median AF duration was 36 months (6-276 months) and majority of patients (49%) are having permanent AF. Based on CHA 2 DS 2 VASc score, subjects are at high risk of stroke with mean score of 3.9 ± 1.63. The clinical characteristics of both patient groups are presented in Table 1 . There was no device replacement due to under-or oversizing. Two patients in Group A implanted second generation of ACP.
In Group B, average size of LAA landing zone and ostial are 22.7 ± 4.87 and 24.3 ± 4.53, respectively. There were no significant differences of ostial diameter measured by TEE vs angiography. However, landing zone diameter is bigger during angiography measurement compared to that measured by TEE (mean difference 3.4 mm, P = 0.008).
Of combine group data, there were no difference of LAA ostium diameter measured by TEE vs angiography. However, LAA landing F I G U R E 2 Amplatzer Cardiac Plug (ACP) placement at the appropriate position. Lobe position is distal to left circumflex (red arrow), and the disk is nicely covering the whole ostial of LAA without protrusion to pulmonary vein nor mitral valve. Left panel shows contrast injection confirm complete LAA closure. The figure is taken from the same patient as Figure 1 zone diameter measured with angiography is bigger compared to that measured with TEE (mean difference 2.8 mm, P = 0.002) ( Table 2 ).
Pericardial effusion complicated two subjects of Group B and one subject of Group A. Two of them need pericardiocentesis. In three subjects of Group B, residual gap (less than 5 mm) is found during TEE follow-up 3 months following implantation.
During the follow-up of almost 19 months, one of the three patients with residual gap experienced stroke at 23 weeks following implantation and another one experienced device-related thrombus.
Transesophageal echocardiography reexamination 3 months after dabigatran 150 mg bid therapy revealed no residual thrombus. The stroke patient completely recovered without sequalae. Ventricle rate is well controlled by beta blocker, nondihydropyridine calcium channel blocker, and digoxin as a single drug or in combination. One patient of both groups died suddenly at the first month. Both patients had significant coronary artery disease and low ejection fraction. Unfortunately, no autopsy was performed. The Kaplan-Meier survival analysis of both groups is shown in Figure 3 . There is no survival different between groups (P = 0.467).
| D ISCUSS I ON
This long-term observational study showed that ACP implantation guided by fluoroscopy only is safe and effective. The successful implantation is 96% which is similar to standard protocol. Nonfatal serious complication occurred in three patients. Complication and mortality rate during implantation and follow-up period were similar to previous study. Urena et al, reported that during mean follow-up of 20 ± 5 months, the rates of death, stroke, systemic embolism, pericardial effusion, and major bleeding were 5.8%, 1.9%, 0%, 1.9%, and 1.9%, respectively. 
| Limitation
Patients assignment is not randomized; however, important clinical characteristics that might influence the outcome were not different between two groups.
| CONCLUSION
ACP implantation guided with fluoroscopy only is feasible and safe. 
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